immunology-2018-keynote

9 / 12

1 5 t h I n t e r n a t i o n a l C o n f e r e n c e o n
Immunology
Journal of Clinical Immunology and Allergy
ISSN 2471-304X
J u l y 0 5 - 0 7 , 2 0 1 8
V i e n n a , A u s t r i a
Immunology 2018
Page 48
Adoptive T cell therapy has been proven to be a promising approach to the
selected cases of cancer therapy. We, however, still need a simple and
standardizedprocedure for producingcancer-specificCD8+Tcells that isgenerally
applicable to most cancers. Based on a unique property of 4-1BB (CD137), the
selective expression of 4-1BB on Ag-engaged T cells, we have developed a
practical protocol to produce antigen-specific CD8+ T cells from peripheral blood
mononuclear cells (PBMCs). We have proven the feasibility of this procedure by
isolating and expanding cytomegalovirus (CMV)-specific CD8+ T cells, and applied
to produce Epstein-Barr virus (EBV)-specific CD8+ T cells. Moreover, our protocol
allowed us to produce CD8+ T cells from cancer patients that were specific for
self/tumor antigens such as hTERT, WT-1, NY-ESO1 and MAGE3 and for neo-
antigens. Our protocol can readily be translated into standard cGMP and is being
used to produce EBV-, hTERT-, and WT-1-specific CD8+ T cells for phase 1 clinical
trials. Among EBV-positive lymphomas, approximately 62% of patients responded
to the 4-1BB CTL therapy including a durable complete regression of 2/2 NK/T
lymphomas with no or minimum toxicity in all patients. We believe that the 4-1BB
CTL will provide a practical and effective method for adoptive T cell therapy in the
clinic.
Biography
Byoung S Kwon has his PhD from the Georgia Regents Uni-
versity, in 1981 and Postdoctoral studies at the Department of
Human Genetics, Yale University from 1981 to 1984. He was a
tenured Professor of the Indiana University School of Medicine,
a Professor and Director of the Immunomodulation Research
Center at the University of Ulsan, a Distinguished Professor and
Investigator at the National Cancer Center, Korea, and Professor
at the Department of Medicine Tulane University, New Orleans
LA. He is currently the Founder and CEO of Eutilex who is devel-
opingTcell therapeutics and immunomodulatory antibody ther-
apeutics. He has published over 300 peer-reviewed papers and
has been serving as an Editorial Member of reputable journals.
4-1BB-based adoptive T cell therapy
Byoung S Kwon
Eutilex Co. Ltd, Korea
Byoung S Kwon, Insights Allergy Asthma Bronchitis 2018, Volume: 4
DOI: 10.21767/2471-304X-C1-001